News | Pharmaceuticals | May 24, 2022

Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules

The U.S. Food and Drug Administration (FDA) announced the recall of the capsules due to dissolution test failure

The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has initiated a voluntary nationwide recall of a single lot of Anagrelide Capsules, USP 0.5 mg (Lot number GD01090), to the consumer level in the United States.

May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has initiated a voluntary nationwide recall of a single lot of Anagrelide Capsules, USP 0.5 mg (Lot number GD01090), to the consumer level in the United States. This voluntary recall was initiated due to dissolution test failure detected during routine stability testing. No other lots are impacted.

Administration of this product with lower dissolution – taking longer to dissolve once ingested – may result in decreased effectiveness or ineffectiveness of the drug to exert its platelet-reducing effect. Failed dissolution can result in a slower rate and extent of drug release leading to less anagrelide available in the body. For seriously ill patients with elevated platelet counts, less available anagrelide in the body could increase the risk of clotting (blood coagulation), and clotting or bleeding events such as a heart attack or stroke, which could be life threatening. To date, Teva has not received any product quality complaints or adverse event reports, of this nature, for the recalled lot.

Anagrelide capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. Information about the affected lot is listed in the table below. It is packed in bottles with 100 Capsules. Teva distributed 4224 bottles nationwide from 07-30-2020 through 09-02-2020 to its wholesale, distributor and retail customers under the label for Teva Pharmaceuticals USA, Inc.

NDC

Lot #

Exp. Date

0172-5241-60 GD01090 05/2022

Teva notified its customers on May 11, 2022, alerting them that the lot was recalled and requesting that they return impacted product. Instructions for returning recalled product and receiving a credit are given in the customer recall letter (Anagrelide Recall 05 2022 Direct Accounts Letter Consumer Level 20 MAY 2022.pdf) and consumer recall letter (Anagrelide Recall 05 2022 _Patient Letter 20 MAY 2022.pdf)released by Teva.

Consumers with questions or concerns should first consult with their health care provider(s). To report an Adverse Event or Quality Complaint, or if you have Medical Related Questions, please use the following contact information:

Medical-related Questions or to report an Adverse Event:
Contact Medical Information at: 888-838-2872, option 3, then, option 4
Live calls received: M - F, 9:00 AM - 5:00 PM Eastern Time; Voicemail: 24 hrs./day, 7 days/week
24 hrs. /day, 7 days/week or by email at [email protected].
Product Quality Complaint-related Questions:
Contact Quality Assurance Services:  888-838-2872, option 4
Live calls received: M - F, 9:00 AM - 5:00 PM Eastern Time; Voicemail: 24 hrs./day, 7 days/week

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

For more information: www.fda.gov

Other recall news:

Medtronic Recalls Harmony Delivery Catheter, Part of TPV System, for Risk of Capsule Break During Use

Pfizer Issues Voluntary Nationwide Recall of ACCUPRIL (Quinapril HCl)

Medtronic Issues Voluntary Recall for Subset of IN.PACT Admiral and IN.PACT AV Drug Coated Balloon

FDA Recalls Quinapril Hydrochloride and Hydrochlorothiazide Tablets by Pfizer

Related Content

News | Heart Failure

June 29, 2022 — A spiral wave of electrical activity in the heart can cause catastrophic consequences. One spiral wave ...

Home June 29, 2022
Home
News | Heart Failure

June 29, 2022 — Adult survivors of cancer have a higher risk of heart failure and other cardiovascular diseases (CVD) ...

Home June 29, 2022
Home
News | Heart Failure

June 29, 2022 — While lower vertebrates can repair their adult hearts after a heart attack, mammals — including humans — ...

Home June 29, 2022
Home
News | Heart Failure

June 27, 2022 — Results from one of the largest global studies of atrial fibrillation (AFib) procedures show that the ...

Home June 28, 2022
Home
News | Heart Failure

June 22, 2022 — Recommendations on how to use gene testing to prevent sudden cardiac death in athletes and enable safe ...

Home June 22, 2022
Home
News | Heart Failure

June 22, 2022— Researchers at The Ohio State University Wexner Medical Center and College of Medicine have developed a ...

Home June 22, 2022
Home
News | Heart Failure

June 20, 2022— Marc Chatzky may not feel like a cardiac pioneer, but he is, at least in South Florida. The Deerfield ...

Home June 20, 2022
Home
News | Heart Failure

June 10, 2022 — Individuals with diabetes display a substantially increased risk of disease in left-sided heart valves ...

Home June 10, 2022
Home
News | Heart Failure

June 9, 2022 — Memorial Regional Hospital recently entered elite company, becoming just the fourth hospital in the ...

Home June 09, 2022
Home
News | Heart Failure

June 3, 3033 — Esperion announced findings from a real-world analysis of more than 400,000 patients at high-risk for ...

Home June 03, 2022
Home
Subscribe Now